Antiluteogenic effects of serial prostaglandin F2α administration in cycling mares.
Abstract: A single dose of PGF2α does not consistently induce luteolysis in the equine CL until at least 5 days after ovulation, leading to the erroneous assumption that the early CL is refractory to the luteolytic effects of PGF2α. We hypothesized that serial administration of PGF2α in early diestrus would induce a return to estrus similar to mares treated with a single injection in mid-diestrus, and fertility of the induced estrus would not differ. The objectives of the study were to evaluate the effects of the 2 approaches as reflected by: (1) concentrations of plasma progesterone; (2) interovulatory and treatment-to-ovulation intervals; (3) the proportion of mares pregnant after artificial insemination. The study consisted of a balanced crossover design in which 10 reproductively normal Quarter Horse Mares were exposed to 2 treatments on 2 consecutive reproductive cycles. At detected ovulation (Day 0), mares were randomly allotted to 1 of 2 treatment groups: I, mid-diestrus treatment, administration of a single 10-mg dose of dinoprost tromethamine (PGF2α) im on Day 10; II, early diestrus treatment, administration of 10-mg PGF2α im twice daily on Days 0, 1, and 2 and once daily on Days 3 and 4. Mares in estrus and with a follicle 35 mm or greater in diameter were artificially inseminated with at least 2 billion motile sperm from a fertile stallion. Pregnancy was defined as detection of a growing embryonic vesicle on 2 consecutive examinations approximately 14 days after ovulation. Serial plasma samples were collected throughout the study period, and concentration of plasma progesterone was determined by RIA. A mixed-model ANOVA for repeated measures was used to analyze hormonal data. Interovulatory and treatment-to-ovulation intervals were compared by a paired t test and fertility by a McNemar chi-square analysis. All mares in group I underwent luteolysis after PGF2α administration denoted by mean (±SD) concentration of plasma progesterone of 0.25 ± 0.21 ng/mL detected 2 days after treatment. In group II, mean concentration of plasma progesterone remained below 1.0 ng/mL during treatment and until the onset of the next estrus. The mean interovulatory interval in group I was 18.5 ± 2.0 days compared with 13.1 ± 3.7 days in group II (P < 0.01). Treatment-to-ovulation intervals were 8.5 ± 2.0 days and 13.1 ± 3.7 days for groups I and II, respectively (P < 0.05). In both groups, 9 of 10 mares were pregnant (P = 1.0). Serial PGF2α administration beginning at ovulation consistently prevented luteal function in 10 of 10 mares in the present study without adversely affecting pregnancy rate of post-treatment cycles.
Copyright © 2014 Elsevier Inc. All rights reserved.
Publication Date: 2014-08-12 PubMed ID: 25234788DOI: 10.1016/j.theriogenology.2014.07.038Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Journal Article
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
The research seeks to disprove the widely held belief that early luteolysis in horses cannot be achieved with a single dose of PGF2α by administering serial PGF2α doses to mares. The study evaluates the two methods on the basis of plasma progesterone levels, interovulatory intervals, treatment-to-ovulation intervals, and achieved pregnancy. The results demonstrate that serial PGF2α administration effectively prevents luteal function without impacting the pregnancy rate.
Study Design
- The research entailed a balanced cross-over design spread over two consecutive reproductive cycles of reproductively healthy Quarter Horse Mares, which were randomly assigned to one of two distinctive treatment groups.
- In Group I, the mares received a single 10-mg dose of dinoprost tromethamine (PGF2α) on Day 10 of detected ovulation (Day 0).
- In Group II, the mares received two daily 10-mg doses of PGF2α on Days 0, 1, and 2, and one daily dose on Days 3 and 4.
AI and Pregnancy Diagnosis
- All mares demonstrating estrus and a follicle of 35mm or more were artificially inseminated with at least two billion motile sperm from a known fertile stallion.
- The presence of a growing embryonic vesicle, determined by two successive examinations around 14 days post-ovulation, marked the confirmation of pregnancy.
Data Collection and Analysis
- Plasma progesterone levels were determined through repeated mixed-model ANOVA tests from serial plasma samples collected throughout the study period.
- The interovulatory period and treatment-to-ovulation intervals were compared by using a paired t-test while fertility was analyzed by a McNemar chi-square analysis.
Results
- In Group I, all the mares underwent luteolysis after treatment. This was indicated by a 0.25 ng/mL mean concentration of plasma progesterone two days after treatment.
- In Group II, the mean concentration of plasma progesterone remained below 1.0 ng/mL during the treatment until the onset of the next estrus cycle.
- The study noted significant differences between the two groups in terms of their interovulatory and treatment-to-ovulation interval. However, there was no significant difference between the two groups in terms of fertility rate, with 9 out of 10 mares in each group successfully impregnated.
This research suggests that administering PGF2α in a serial manner can effectively prevent luteal function in mares without negatively impacting their subsequent fertility rates.
Cite This Article
APA
Coffman EA, Pinto CR, Snyder HK, Leisinger CA, Cole K, Whisnant CS.
(2014).
Antiluteogenic effects of serial prostaglandin F2α administration in cycling mares.
Theriogenology, 82(9), 1241-1245.
https://doi.org/10.1016/j.theriogenology.2014.07.038 Publication
Researcher Affiliations
- Department of Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio, USA.
- Department of Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio, USA. Electronic address: cpinto@lsu.edu.
- Department of Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio, USA.
- Department of Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio, USA.
- Department of Animal Sciences, The Ohio State University, Columbus, Ohio, USA.
- Department of Animal Science, North Carolina State University, Raleigh, North Carolina, USA.
MeSH Terms
- Analysis of Variance
- Animals
- Dinoprost / pharmacology
- Estrus / drug effects
- Fertility
- Horses / metabolism
- Horses / physiology
- Luteolysis / drug effects
- Luteolytic Agents / pharmacology
Citations
This article has been cited 0 times.Use Nutrition Calculator
Check if your horse's diet meets their nutrition requirements with our easy-to-use tool Check your horse's diet with our easy-to-use tool
Talk to a Nutritionist
Discuss your horse's feeding plan with our experts over a free phone consultation Discuss your horse's diet over a phone consultation
Submit Diet Evaluation
Get a customized feeding plan for your horse formulated by our equine nutritionists Get a custom feeding plan formulated by our nutritionists